Your SlideShare is downloading. ×
0
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
09.00 09.30 mark rupp - publiceren
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

09.00 09.30 mark rupp - publiceren

133

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
133
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Srinivasan A, et al. MMWR 60: 2011; CDC BHSN 2010 Data Summary; Umscheid CA, et al. Infect Control Hosp Epidemiol. 2011; 32:101-114.Scott RD. Division of Healthcare Quality Promotion, CDC, 2009.
  • 2. CHG/SS M/R Silver/Platinum/ Carbon (Silver Iontophoretic; Vantex) Hydrocath Assure (BD) Benzalkonium AMC Thromboshield (Edwards)Multistar Benzalkonium HeparinMiconazole/Rifampin(Vygon)
  • 3. Staphylococcus epidermidisC/S CS/C/P M/R Spangler & Moss, Arrow International
  • 4. Pseudomonas aeruginosa Candida albicans C/S C/S C C S/C/P M/R S/C/P M/R Spangler & Moss, Arrow InternationalCH/SS: Poor activity vs Acinetobacter,Stenotrophomonas, Enterobacter
  • 5. Meta Analysis Medline search of articles with “meta-analysis” in title, 2007-2011  Quality of Reporting of Meta-Analysis (QUORUM) guidelines
  • 6. BSI Silver Alloy (0.58) Silver Iontoph (1.98) Silver Impreg (0.93) BenzChl (1.0) Colonization Silver Alloy (1.21) Rif/Micon (0.14)Casey AL, et al. Lancet ID, 2008
  • 7. Ramritu AJIC 2008Scatter plot of 29 studies (BSI vs. colonization)Spearman Correlation coefficient:r = 0.63, r2 = 0.4; P = 0.003
  • 8. Do antimicrobial-coated catheters prevent BSI? 4.2% 0.68 0.47 2.3% 0.29 5.9% Casey AL, et al. Lancet ID, 2008
  • 9. S. aureus S. epidermidis1st & 2nd generation CH/SS CVCs 2nd generation CH/SS CVC 2 (58 explanted CVCs) 1 Bassetti, et al AAC 2001 Fey et al, ICAAC, 2000 Duration of activity of M/R appears to be greater than CH/SS
  • 10. Chest, 2004
  • 11. Crit Care Med, 2011
  • 12. Veenstra DL, et al. JAMA 1999 Shorr AF, et al. Chest 2003Marciante KD, et al. AJIC 2003
  • 13. Conclusions from Cost Effectiveness StudiesVeenstra DL, et al. JAMA 1999“…the use of chlorhexidine-silver sulfadiazine impregnated cathetersin patients at high risk for infection reduces the incidence of CR-BSIand death and provides significant saving in costs.”Shorr AF, et al. Chest 2003“Utilization of antiseptic and antibiotic-impregnated CVCs representan attractive alternative for prevention of CRBSIs and may lead tosignificant savings. … the RM CVC performs better financially.”Marciante KD, et al. AJIC 2003“CVCs coated with M/R are cost effective for patients catheterizedfor at least one week and lead to overall cost savings when patientsare catheterized for 2 weeks or longer.”
  • 14. Health Technology Assessment, 2008
  • 15. Crit Care, 2009
  • 16. (MRSA) GND X M/R * CH/SS SPC
  • 17. Spectrum of ActivityMRSA P.aer C. albicans C. glabrata Uncoated M/R CH-M/R CH/SS Durability vs MRSA Uncoated M/R CH-M/R CH/SS
  • 18. Kaplan Meier analysis of colonization Walz, et al. Crit Care Med, 2010

×